Patient Voice Missing In Asthma Drug Safety Debate – FDA’s Jenkins

29 Oct 2012
News

Sue Sutter @PinkSheetSutter sue.sutter@informa.com

Executive Summary

When a post-marketing safety signal arises, patients’ perspective of benefit is often drowned out by consumer advocates’ worries about a drug’s risks, the Office of New Drugs director says.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

United States

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

BioPharmaceutical United States Risk Management

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS054850

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS054850

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Patient Voice Missing In Asthma Drug Safety Debate – FDA’s Jenkins

News

Executive Summary

Related Content

Death Vs. Symptomatic Relief – Weighing Risks And Benefits For Asthma Drugs

FDA Panels Favor Advair, Symbicort Over Single-Entity LABAs For Asthma

Topics

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert